Effects of single-dose l-asparaginase on coagulation values in healthy dogs and dogs with lymphoma

Kenita S. Rogers From the Departments of Small Animal Medicine and Surgery (Rogers, Barton) and Veterinary Pathobiology (Benson, Green), College of Veterinary Medicine, Texas A&M University, College Station, TX 77843-4474.

Search for other papers by Kenita S. Rogers in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Claudia L. Barton From the Departments of Small Animal Medicine and Surgery (Rogers, Barton) and Veterinary Pathobiology (Benson, Green), College of Veterinary Medicine, Texas A&M University, College Station, TX 77843-4474.

Search for other papers by Claudia L. Barton in
Current site
Google Scholar
PubMed
Close
 DVM
,
Patricia A. Benson From the Departments of Small Animal Medicine and Surgery (Rogers, Barton) and Veterinary Pathobiology (Benson, Green), College of Veterinary Medicine, Texas A&M University, College Station, TX 77843-4474.

Search for other papers by Patricia A. Benson in
Current site
Google Scholar
PubMed
Close
 BS
, and
Robert A. Green From the Departments of Small Animal Medicine and Surgery (Rogers, Barton) and Veterinary Pathobiology (Benson, Green), College of Veterinary Medicine, Texas A&M University, College Station, TX 77843-4474.

Search for other papers by Robert A. Green in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Click on author name to view affiliation information

Summary

Ten healthy dogs and 10 dogs with multicentric lymphoma were given a single dose of l-asparaginase at a rate of 10,000 IU/m2 of body surface. Assessment of concentrations of contributors to the coagulation process and of the ability to coagulate including antithrombin III, one-stage prothrombin time, prothrombin-proconvertin time, activated partial thromboplastin time, plasminogen, fibrinogen, and platelet number were performed prior to drug administration (day 0). These tests were repeated 24 hours (day 1), 48 hours (day 2), and 7 days after treatment with l-asparaginase. Antithrombin-III concentrations were significantly lower in the dogs with lymphoma than in healthy dogs on days 0, 1, 2, and 7; however, with the exception of day 1, mean values remained within normal limits. There was also a difference between the 2 groups in prothrombin/proconvertin values on day 7 and in platelet number on day 2, with the lymphoma group having significantly shorter prothrombin/proconvertin time than healthy dogs, and the difference in platelet numbers being associated with increased counts in the healthy dogs. Data obtained from the healthy dogs and dogs with lymphoma for each coagulation test were pooled for each treatment day (0, 1, 2, and 7), and day-0 values for each coagulation test were compared with data obtained on days 1, 2, and 7. Antithrombin-III concentration on day 7 was significantly lower than on day 0, prothrombin/ proconvertin time on day 1 was significantly longer than on day 0, and fibrinogen concentrations on days 1 and 2 were significantly lower than on day 0. Evidence of clinical hemorrhage or thrombosis was not found in any dog subsequent to l-asparaginase administration. Results of this study suggest that although individual coagulation test results may be altered, a single dose of l-asparaginase does not clinically alter coagulation in either healthy dogs or dogs with multicentric lymphoma.

Summary

Ten healthy dogs and 10 dogs with multicentric lymphoma were given a single dose of l-asparaginase at a rate of 10,000 IU/m2 of body surface. Assessment of concentrations of contributors to the coagulation process and of the ability to coagulate including antithrombin III, one-stage prothrombin time, prothrombin-proconvertin time, activated partial thromboplastin time, plasminogen, fibrinogen, and platelet number were performed prior to drug administration (day 0). These tests were repeated 24 hours (day 1), 48 hours (day 2), and 7 days after treatment with l-asparaginase. Antithrombin-III concentrations were significantly lower in the dogs with lymphoma than in healthy dogs on days 0, 1, 2, and 7; however, with the exception of day 1, mean values remained within normal limits. There was also a difference between the 2 groups in prothrombin/proconvertin values on day 7 and in platelet number on day 2, with the lymphoma group having significantly shorter prothrombin/proconvertin time than healthy dogs, and the difference in platelet numbers being associated with increased counts in the healthy dogs. Data obtained from the healthy dogs and dogs with lymphoma for each coagulation test were pooled for each treatment day (0, 1, 2, and 7), and day-0 values for each coagulation test were compared with data obtained on days 1, 2, and 7. Antithrombin-III concentration on day 7 was significantly lower than on day 0, prothrombin/ proconvertin time on day 1 was significantly longer than on day 0, and fibrinogen concentrations on days 1 and 2 were significantly lower than on day 0. Evidence of clinical hemorrhage or thrombosis was not found in any dog subsequent to l-asparaginase administration. Results of this study suggest that although individual coagulation test results may be altered, a single dose of l-asparaginase does not clinically alter coagulation in either healthy dogs or dogs with multicentric lymphoma.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 66 66 17
PDF Downloads 54 54 14
Advertisement